Ang Lifesciences India Ltd. · BSE:ANG
Ang Lifesciences India — Investor Presentation (August 2021)
26 slides from Ang Lifesciences India's investor presentation, August 2021
Slide 1: Corporate Presentation August 2021
YOUR TRUSTED As ASSOCIATE IN ) HEALTHCARE ANG LIFESCIENCES CORPORATE PRESENTATION AUGUST, 2021
Slide 2: Safe Harbor
09 SAFE HARBOR Certain statements in thisdocument maybe forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions,local political or economic developments, technological risks, and many other factors that could cause our actual
Slide 3: Business Highlights
BUSINESS HIGHLIGHTS ING LIFESCIENCES INDIA LIMITED - A Listed Pharma company with a Pure-Play Formulation Model. : Strong Traction across Formulation Supply Chain comprising Government Institutional Segment, Third Party Manufacturing/ Contract Manufacturing Exports and Direct Marketing . : Focused P
Slide 4: Overview
OVERVIEW ANG LIFESCIENCES INDIA LIMITED REVENUE SEGMENT Third Party/Contract Manufacturing, Exports Government Institutions and Direct marketing WHERE WE MAKE? MARKET -Baddi, Himachal Pradesh INFORMATION COUNTRIES WE - ANG’s equity shares are — listed and actively traded on the EXPORT BSE SME Platfo
Slide 5: Company milestones timeline
2006-07 nw Company ot incorporated TaN 2021-22 on June 14, 2006 Acquired MBP Pharma Ltd Ss ene and also acquired 2 Units oT ~sN na En of Ind-swift Ltd. Unit 5 x eo. llalnieien ; a aaa ----~_ «commercial production i N ye eee clvak I , Company exhibited S Disruptive growth in J the turnover by 140% P
Slide 6: Mission and vision
ais. ANG LIFESCIENCES INDIA LIMITED We are driven by our passion toreach every Hospital with our Quality Products in Critical care treatment. Committed to provide Medicines on Affordable Prices around the Globe for betterment of Mankind.
Slide 7: Management team
POOL ANG LIFESCIENCES INDIA LIMITED Mrs. Saruchi Gupta Mr. Anjani Kumar Singh Mr. Dinesh Bajola (GM Quality) Non Executive Director (New Product Development M.Sc in Organic Chemistry with Commerce graduate with 15 Head) 25 years of Rich working years of experience. experience of Quality Control. Ext
Slide 8: Strength by Strength
STRENGTH BY STRENGTH ING LIFESCIENCES INDIA LIMITED Facilities Accredited by International Reg State-of-the-art Manufacturing Capabilities Internationally Benchmarked Quality and Regulatory Systems Customer Relationship through Outstanding Products and Services Pan India Presence Approved Vendors fo
Slide 9: Quality
QUALITY ANG LIFESCIENCES INDIA LIMITED MOH YEMEN MOH COMBODIA MOH SENEGAL MOH BOLIVIA MOH CONGO MOH GHANA MOH LIBYA QUALITY MANAGEMENT SYSTEM
Slide 10: Global & Domestic Pharmaceutical Market
A Fae GLOBAL & DOMESTIC ANG LIFESCIENCES INDIA LIMITED INDIAN Pharmaceutical According to the Indian Market: Economic Survey 2021, the The global pharmaceuticals market domestic market is expected to reached a value of nearly $1,217.1 India is the largest provider of generic grow 3x in the next deca
Slide 11: Business Strategy
dy LEX BUSINESS STRATEGY ANG LIFESCIENCES INDIA LIMITED \ . To Increase Market Share ; Deeper Penetration Through Domestic Branding Market Development; Increase Geographical Footprints by Product Registration Product Development; By adding 50 Product formulations in current FY ® Growth Strategy ; Th
Slide 12: Leading Brands
dy Zan. LEADING BRANDS ANG LIFESCIENCES INDIA LIMITED AGCLAV Amoxycillin & Potassium Clavulanate Inj. CLONE Ceftriaxone Sodium Injection IP LANGICIN Clarithromycin Injection eEffective in the treatment of Acute eRapid clinical response in the eAnti-Inflammatory & Immunomodulatory Bronchitis, Sinusit
Slide 13: Leading Brands
LEADING BRANDS ANGLIFESCIENCES INDIA LIMITED <a s ss Esomeprazole = for Injection =~ EOME t \ | “elt P| Qiid = HeovOT ee | ANGITAX a = veroeren tom = TT . Injection IP > — NOVOMERO » Powedes tor biavenoet Irvectine us Infuse = Ss a 5 13
Slide 14: Clientele
o CLIENTELE “IRESCIE ANG LIFESCIENCES INDIA LIMITED A HETERO HEALTHCARE AFMSD GLAND Armed Forces Medical Stores Py GLAND PHARMA LIMITED Depot Haryana Medical Services Corporation Ltd. (A Govt. of Haryana Undertaking) 14
Slide 15: How We Grow?
A Be HOW WE GROW ? INCLEESINCES INDIA LIMITED Share of Export in Total Revenue ANG's more than 50 Product Registrations are under way(Under Registration) in countries like Yemen ,Latin America,Philippines, Vietnam, Myanmar, Uganda, Kenya, Ghana, Nigeria, Congo, Libya, Combodia, Senegal, Togo, Bolivi
Slide 16: Financial Snapshot
AN Financial Snapshot LB ANG LIFESCIENCES INDIA LIMITED Rs. In Lacs 2013 yA 2015 2016 2017 yAOKE:} 2019 2020 2021 Income Income from 1624.13 | 3449.93 | 3684.16 5492.3 | 6766.81 | 7604.47 | 12169.98 | 12683.11 | 15437.89 Operations Other Income 3.73 9.46 9.46 21.03 25.02 68.72 23.27 41.97 55.58 Tota
Slide 17: Financial Snapshot
. . LEE & Financial Snapshot ANG LIFESCIENCES INDIA LIMITED NAOT Com toe last 5 years —__—_. 1H EPZe ™ Revenue PAT < Lakh La YoY — La gE Rs) Growth cha) 15493.48 5513.32 27% FY 16 FY21 YoY : : Growth , Ba 15493.48 1628.64 v¥ Net Debt 7 CR FY13 FY21 ¥ Maintained ROCE at >= 22% overlast 6 years ¥ Curr
Slide 18: Track Record of Value-Accretive Growth
Track Record Of Value -Accretive Growth as ANG LIFESCIENCES INDIA LIMITED Revenue (2 Lakh) EBITDA (% Lakh) & % PAT (% Lakh) & % 702.76 CAGR 15493.48 CAGR 1013.9 30% CAGR 30% 27% a 165.48 5513.32 FY16 FY21 FY16 FY21 FY16 FY21 EPS (% OCF as % of EBITDA 13.77 87% CAGR 27% 3.24 FY16 FY21 FY16 FY21 Sourc
Slide 19: Financial Profile
a AIDS i “é~ sj x aN FINANCIAL PROFILE INC LIFESCIENCES INDIA LIMITED Total revenue increased by 30% CGAR INR 15493.33 Lakh in FY-2021 from INR 5513.32 Lakh in FY 2015-16 The Company’s EBITDA increased by 30% CGAR INR 1013.9 Lakh in FY21 from INR 222.06 Lakh in FY 16, owing to strong product demand,
Slide 20: Acquisitions Created Synergy for ANG
ACQUISITIONS CREATED SYNERGY FOR ANG ahs ANG LIFESCIENCES INDIA LIMITED ANG is Company has M/s. Star M/s ANG acquired metamorphosing acquired Assets of Biotech: A MBP Pharma in it, from two sick units Pharma company Jan 21 and also Manufacturing under distress engaged into Dry Powder sale: M/s.Star
Slide 21: Current Capacity and Upcoming Facility
ais Current Capacity and Upoming Facility ANG LIFESCIENCES INDIA LIMITED Current Capacity of our Products WHO GIP facility at Baddi Products Capacity ( in Mn Units) Per Annum Tablets 3000 Liquid injection 90 Ampoules Liquid Injection Vials 48 Liquid Syrup 120 Dry Syrup 12 Brownfield facility Star Bi
Slide 22: Outlook FY22 & Way Forward
A ZN Outlook FY22 & Way Forward..... ING LIFESCIENCES INDIA LIMITED » Confident to Post 400 to 450 Cr. Revenue in Current FY post Acquisition of Two Pharma Formulation Units from M/s Ind- Swift Ltd. » Aims to achieve Revenue of 800 -850 Cr in FY 22-23 through Domestic Brand building, Manufacturing o
Slide 23: Key Growth Drivers
& Key Growth Drivers ANG LIFESCIENCES e LEE INDIA LIMITED ¢ Our Business model of Building Strong and Sustainable Products Expansion of has enabled us to maintain our growth trajectory during pandemic Product periods (Wave 1 as well as Wave 2). Portfolio ¢ Our Market Standing in Dry Powder Injectabl
Slide 24: Key Growth Drivers
& BBS Key Growth Drivers ANGLIFESCIENCES INDIA LIMITED Expansion of ¢ We plan to significantly expand our coverage of more Export Market Geographies and Product Segments. * We are investing in diversification opportunities in high-growth Therapeutic areas like Therapeutic Segment such as Cream and O
Slide 25: 2021-22 Asset Purchase Deal with Ind-Swift
a 2021-22 ING LFESCLENCE INDIA LIMITED ANG Lifesciences India Limited has executed an Asset Purchase Deal with Ind-Swift Limited for acquisition of Two Formulation Manufacturing Facilities for INR 60 Cr. Payable through internal accrual & bank funding on deferred payment basis up to 30Jun-2024. Unit
Slide 26: Thank You
Za. ANG LIFESCIENCES INDIA LIMITED THANK YOU For more information, please contact: Ms. RENU KAUR (Company Secretary) ANG Lifesciences India Ltd. SCO 113, 1st Floor, Darbara Complex, Ranjit Avenue, B-Block, Amritsar-143001, INDIA. Tel: 0183-5133473 E-Mail: [email protected] | cs@anglifescience
ANG Lifesciences India — Investor Presentation (August 2021) on 6ix